Pegozafermin (BIO89-100) Market

"Pegozafermin (BIO89-100) Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Pegozafermin (BIO89-100) for Liver fibrosis in the 7MM. A detailed picture of the Pegozafermin (BIO89-100) for Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Pegozafermin (BIO89-100) for Liver fibrosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Pegozafermin (BIO89-100) market forecast, analysis for Liver fibrosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Liver fibrosis.

Drug Summary

Pegozafermin was engineered using a proprietary glycoPEGylation technology to prolong the biological activity of fibroblast growth factor 21 (FGF21) while maintaining the efficacy of native FGF21. FGF21 is an endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. Pegozafermin has the potential to be the best-in-class FGF21 analog based on the current clinical profile, which delivers a compelling risk-benefit profile with the tolerability and dosing convenience necessary for adoption and compliance.

As pegozafermin improves liver pathology and addresses underlying metabolic issues, 89bio is studying it in non-alcoholic steatohepatitis (NASH). Recent results showed robust reductions in liver fat with a significant percentage of patients seeing clinically meaningful responses. Further, robust results were observed on key liver markers relevant in NASH. Strong efficacy and favorable tolerability were observed with weekly and every two-week dosing.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Pegozafermin (BIO89-100) description, mechanism of action, dosage and administration, research and development activities in Liver fibrosis.
• Elaborated details on Pegozafermin (BIO89-100) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Pegozafermin (BIO89-100) research and development activity in Liver fibrosis in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Pegozafermin (BIO89-100).
• The report contains forecasted sales of Pegozafermin (BIO89-100) for Liver fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Liver fibrosis.
• The report also features the SWOT analysis with analyst views for Pegozafermin (BIO89-100) in Liver fibrosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pegozafermin (BIO89-100) Analytical Perspective by DelveInsight

In-depth Pegozafermin (BIO89-100) Market Assessment

This report provides a detailed market assessment of Pegozafermin (BIO89-100) in Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of pegozafermin.

Pegozafermin (BIO89-100) Clinical Assessment

The report provides the clinical trials information of Pegozafermin (BIO89-100) in Liver fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Liver fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pegozafermin (BIO89-100) dominance.
• Other emerging products for Liver fibrosis are expected to give tough market competition to Pegozafermin (BIO89-100) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pegozafermin (BIO89-100) in Liver fibrosis.
• Our in-depth analysis of the forecasted sales data of pegozafermin (BIO89-100) will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Pegozafermin (BIO89-100) in Liver fibrosis.

Key Questions

• What is the product type, route of administration and mechanism of action of Pegozafermin (BIO89-100)?
• What is the clinical trial status of the study related to Pegozafermin (BIO89-100) in Liver fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pegozafermin (BIO89-100) development?
• What are the key designations that have been granted to Pegozafermin (BIO89-100) for Liver fibrosis?
• What is the forecasted market scenario of Pegozafermin (BIO89-100) for Liver fibrosis?
• What are the forecasted sales of Pegozafermin (BIO89-100) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Liver fibrosis and how are they giving competition to Pegozafermin (BIO89-100) for Liver fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of Liver fibrosis?